Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 69Osteosarcoma 29Sarcoma, Ewing 20Rhabdomyosarcoma 17Ovarian Neoplasms 17Melanoma 17Neuroblastoma 15Gastrointestinal Stromal Tumors 15Colorectal Neoplasms 12Bone Neoplasms 12Wilms Tumor 11Sarcoma, Kaposi 11Rhabdoid Tumor 11Neoplasms 11Lymphoma, Non-Hodgkin 10Hepatoblastoma 10Glioma 10Breast Neoplasms 10Stomach Neoplasms 9Medulloblastoma 9Liposarcoma 9Ependymoma 9Neurofibrosarcoma 8Neuroectodermal Tumors, Primitive, Peripheral 8Neoplasm Metastasis 8Head and Neck Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Carcinoma, Hepatocellular 8Prostatic Neoplasms 7Pancreatic Neoplasms 7

Interventions

temsirolimus 1Vinorelbine 1Vincristine 1Sirolimus 1Radiotherapy 1Radiation 1Irinotecan 1Dactinomycin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rhabdomyosarcoma, Embryonal × Sarcoma × 30 days × Clear all
NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
325 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡